Enter your keywords

NICE TA875; Semaglutide for managing obesity: A briefing for ICSs  

In March 2023 NICE published TA875: Technology Appraisal guidance for semaglutide (Wegovy®) for managing overweight and obesity. The guidance recommends semaglutide as an option for weight management when prescribed by a specialist service alongside a reduced-calorie diet and increased physical activity in adults if they meet the criteria specified. This briefing aims to provide advice […]

Budget impact of metformin 1g immediate release tablet prescribing

The purpose of this bulletin is to highlight the rapid increase in price of metformin 1g tablets over the last year, and to raise awareness of the difference in price of metformin 1g immediate release (IR) tablets compared with 500mg IR tablets. It considers the potential budget impact to primary care of prescribing metformin 1g […]

Atrial Fibrillation [NICE NG196]: Financial and commissioning impact

In April 2021, NICE published a new guideline NG196 – Atrial fibrillation: diagnosis and management which updates and replaces NICE CG180 (2014). There are a number of new recommendations, which are likely to have both a significant financial impact and potentially affect the way anticoagulation monitoring is managed. This bulletin aims to raise awareness of […]

Impact of Priadel Price Change on CCG Prescribing Budgets

This bulletin aims to raise awareness of the NHS price increase for Priadel® (lithium carbonate) tablets as of November 2020 and the resulting cost impact to primary care. While discussions between the DHSC and the manufacturer of Priadel have prevented its discontinuation from the UK market at this stage, the renegotiated price in November 2020 […]

Oral Vitamin B supplementation

This document aims to support the Regional Medicines Optimisation Committees (RMOC) position statement; “Oral vitamin B supplementation in alcoholism” by identifying CCGs and geographical areas where prescribing within primary care may not be in line with the recommendations. There is ongoing prescribing of vitamin B complex products despite national and local recommendations that this should […]

Long-Term Use Of PPIs – Bulletin

Long-term use of PPIs is not recommended in several indications as it has been linked to adverse effects including hypomagnesaemia, vitamin B12 deficiency, increased fracture risk and increased risk of MI. This bulletin aims to highlight the current national guidance, potential adverse effects associated with long term PPI use and prescribing patterns on a CCG […]